摘要
背景:ARRDC3是哺乳动物α-arrestins家族中的一员,在人类乳腺癌中被确定为肿瘤抑制基因,但在人类前列腺癌(PCa)中其功能尚不清楚, 。 目的:本研究旨在探讨PCa中ARRDC3失调的临床意义,生物学功能及其机制。 方法:通过临床样本评估,微阵列分析以及体外和体内实验来证明ARRDC3失调在PCa的恶性表型中的参与。确定了其对肿瘤进展的调节作用的机制。 结果:基因芯片分析发现ARRDC3低表达与TMA高Gleason评分显着相关,在线Taylor数据集中ARRDC3表达水平与Gleason评分,转移及生化复发呈负相关。 Kaplan-Meier分析显示,ARRDC3高表达的PCa患者的生化无复发生存期(BCR-free)时间长于ARRDC3低表达的患者。此外,单变量和多变量分析均显示,ARRDC3的下调是PCa患者无BCR生存的独立预后指标。体外研究表明,ARRDC3可以抑制PCa细胞的增殖,迁移和侵袭。体内研究证明,与对照相比,ARRDC3过表达细胞形成显着更大的肿瘤结节并显着加速肿瘤异种移植物生长。此外,Ki67和MMP-9的免疫组化评分显着低于对照组。最后,相关性分析表明ARRDC3的表达与ITGβ4在临床PCa组织和细胞系中呈负相关。 结论:我们的数据显示,ARRDC3可作为抑制PCa进展的肿瘤抑制因子,是预测PCa根治性切除后生化复发转移的独立指标。
关键词: 前列腺癌,包含抑制结构域的蛋白质3,进展,整合素,肿瘤抑制剂,ITGβ4。
Current Molecular Medicine
Title:ARRDC3 Inhibits the Progression of Human Prostate Cancer Through ARRDC3-ITGβ4 Pathway
Volume: 17 Issue: 3
关键词: 前列腺癌,包含抑制结构域的蛋白质3,进展,整合素,肿瘤抑制剂,ITGβ4。
摘要: Background: Arrestin domain-containing protein 3 (ARRDC3) is a member of the mammalian α-arrestins family, which has been identified as a tumor suppressor gene in human breast cancer, but its functions are still not clear in human prostate cancer (PCa).
Objective: The purpose of the present study was to investigate clinical significance, biological functions and underlying mechanisms of ARRDC3 deregulation in PCa.
Method: Involvement of ARRDC3 deregulation in malignant phenotypes of PCa was demonstrated by clinical sample evaluation, microarray analysis, and in vitro and in vivo experiments. The mechanisms underlying its regulatory effect on tumor progression were determined.
Results: Microarray analysis found that ARRDC3 low expression was significantly associated with high Gleason score in TMA, and the expression level of ARRDC3 was negatively correlated with Gleason score, metastasis and biochemical recurrence in online Taylor Dataset. As revealed by the dataset, Kaplan-Meier analyses revealed that the biochemical recurrence-free survival (BCR-free) time of PCa patients with ARRDC3 high expression was longer than those with ARRDC3 low expression. Additionally, both univariate and multivariate analyses showed that the downregulation of ARRDC3 was an independent prognostic marker for BCR-free survival of patients with PCa. In vitro studies revealed that ARRDC3 could inhibit proliferation, migration and invasion of PCa cell lines. In vivo studies proved that ARRDC3 over-expressing cells formed significantly larger tumor nodules and remarkably speeded up tumor xenografts growth compared with the controls. Moreover, immunohistochemical scores of Ki67 and MMP-9 were significantly lower than those of the control group. Finally, correlation analysis indicated that the expression of ARRDC3 was negatively correlated with ITGβ4 in clinical PCa tissues and cell lines.
Conclusion: Our data revealed that ARRDC3 can serve as a tumor suppressor to inhibit PCa progression and an independent marker to predict the risk of biochemical recurrence and metastasis after radical resection of PCa.
Export Options
About this article
Cite this article as:
ARRDC3 Inhibits the Progression of Human Prostate Cancer Through ARRDC3-ITGβ4 Pathway, Current Molecular Medicine 2017; 17 (3) . https://dx.doi.org/10.2174/1566524017666170807144711
DOI https://dx.doi.org/10.2174/1566524017666170807144711 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chemical Characterization of Phytochemicals of Cucurbitaceae Family by Gas Chromatography – Mass Spectroscopy
Current Traditional Medicine Gene Sets of Gene Ontology are More Stable Diagnostic Biomarkers than Genes in Oral Squamous Cell Carcinoma
Current Bioinformatics The Link Between CD6 and Autoimmunity: Genetic and Cellular Associations
Current Drug Targets Editorial [Hot topic: Targeting Nitric Oxide for Tumor Therapy (Executive Editor: Antonio Contestabile)]
Current Pharmaceutical Design Cellular Membranes and Lipid-Binding Domains as Attractive Targets for Drug Development
Current Drug Targets High Performance Liquid Chromatographic Approaches to Mass Spectrometry Based Metabolomics
Current Metabolomics Update on Intravenous Immunoglobulins (IVIg) Mechanisms of Action and Off- Label use in Autoimmune Diseases
Current Pharmaceutical Design DNA Damage-inducing Compounds: Unraveling their Pleiotropic Effects Using High Throughput Sequencing
Current Medicinal Chemistry Simultaneous Amplification of HER-2 (ERBB2) and Topoisomerase IIα (TOP2A) Genes - Molecular Basis for Combination Chemotherapy in Cancer
Current Cancer Drug Targets E-Cadherin Upregulation as a Therapeutic Goal in Cancer Treatment
Mini-Reviews in Medicinal Chemistry Design, Synthesis and Anticancer Evaluation of Carbazole Fused Aminopyrimidine Derivatives
Letters in Organic Chemistry Synthesis and Cytotoxicity Assessment of Novel 7-O- and 14-O-Derivatives of Glaucocalyxin A
Anti-Cancer Agents in Medicinal Chemistry Epothilones: A Novel Class of Non-taxane Microtubule-stabilizing Agents
Current Pharmaceutical Design Role of Forkhead Transcription Factors of the O Class (FoxO) in Development and Progression of Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Metallic Nanoparticles as SERS Agents for Biomolecular Imaging
Current Pharmaceutical Biotechnology Genomics Can Advance The Potential For Probiotic Cultures To Improve Liver And Overall Health
Current Pharmaceutical Design Synthesis of Some 1-(Flavon-7-yl)-4,5-dihydro-1,2,4-triazin-6(1H)-ones and Related Congeners
Letters in Organic Chemistry Histone Deacetylase Inhibitors: Recent Insights from Basic to Clinical Knowledge & Patenting of Anti-Cancer Actions
Recent Patents on Anti-Cancer Drug Discovery Heparan Sulphate as a Regulator of Leukocyte Recruitment in Inflammation
Current Protein & Peptide Science Phytochemicals to Prevent Inflammation and Allergy
Recent Patents on Inflammation & Allergy Drug Discovery